MX2023007641A - Derivados de 4-amino-3-(4-fenoxifenilo)-1,3-dihidro-2h-imidazo[4,5 -c]piridin-2-ona y sales de los mismos. - Google Patents

Derivados de 4-amino-3-(4-fenoxifenilo)-1,3-dihidro-2h-imidazo[4,5 -c]piridin-2-ona y sales de los mismos.

Info

Publication number
MX2023007641A
MX2023007641A MX2023007641A MX2023007641A MX2023007641A MX 2023007641 A MX2023007641 A MX 2023007641A MX 2023007641 A MX2023007641 A MX 2023007641A MX 2023007641 A MX2023007641 A MX 2023007641A MX 2023007641 A MX2023007641 A MX 2023007641A
Authority
MX
Mexico
Prior art keywords
phenoxyphenyl
imidazo
dihydro
derivatives
salts
Prior art date
Application number
MX2023007641A
Other languages
English (en)
Inventor
Catherine Arabeyre
Patricia Moliner
Sabine Boisnard
Damien Sallaberry
Serge Perard
Sebastien Roy
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2023007641A publication Critical patent/MX2023007641A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se refiere a variantes o derivados de 4-amino-3-(4-fenoxifenilo)-1,3-dihidro-2H-imidazo0[4,5-c]piridin- 2-ona y sales de los mismos para utilizar como agonistas y antagonistas. La divulgación además se refiere a composiciones, métodos de preparación y métodos de tratamiento.
MX2023007641A 2020-12-23 2021-12-22 Derivados de 4-amino-3-(4-fenoxifenilo)-1,3-dihidro-2h-imidazo[4,5 -c]piridin-2-ona y sales de los mismos. MX2023007641A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063130010P 2020-12-23 2020-12-23
US202163245288P 2021-09-17 2021-09-17
PCT/US2021/064800 WO2022140511A1 (en) 2020-12-23 2021-12-22 4-amino-3-(4-phenoxyphenyl)-1,3- dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof

Publications (1)

Publication Number Publication Date
MX2023007641A true MX2023007641A (es) 2023-07-07

Family

ID=79730613

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007641A MX2023007641A (es) 2020-12-23 2021-12-22 Derivados de 4-amino-3-(4-fenoxifenilo)-1,3-dihidro-2h-imidazo[4,5 -c]piridin-2-ona y sales de los mismos.

Country Status (11)

Country Link
US (1) US20240051955A1 (es)
EP (1) EP4267572A1 (es)
JP (1) JP2024501247A (es)
KR (1) KR20230124663A (es)
AU (1) AU2021409575A1 (es)
CA (1) CA3206176A1 (es)
CO (1) CO2023009491A2 (es)
IL (1) IL303834A (es)
MX (1) MX2023007641A (es)
TW (1) TW202241887A (es)
WO (1) WO2022140511A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023244587A1 (en) * 2022-06-14 2023-12-21 Genzyme Corporation Methods of making tolebrutinib
WO2023249980A1 (en) * 2022-06-22 2023-12-28 Genzyme Corporation Methods of making modified btk inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086358A1 (en) * 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Hydroxymethyl piperidine orexin receptor antagonists
PL3303334T3 (pl) * 2015-06-03 2021-11-08 Principia Biopharma Inc. Inhibitory kinaz tyrozynowych

Also Published As

Publication number Publication date
CA3206176A1 (en) 2022-06-30
IL303834A (en) 2023-08-01
EP4267572A1 (en) 2023-11-01
WO2022140511A1 (en) 2022-06-30
TW202241887A (zh) 2022-11-01
KR20230124663A (ko) 2023-08-25
CO2023009491A2 (es) 2023-07-31
JP2024501247A (ja) 2024-01-11
US20240051955A1 (en) 2024-02-15
AU2021409575A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
MX2023007641A (es) Derivados de 4-amino-3-(4-fenoxifenilo)-1,3-dihidro-2h-imidazo[4,5 -c]piridin-2-ona y sales de los mismos.
TN2012000265A1 (en) Triazolopyridines
MX2018003215A (es) Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
GB201104267D0 (en) Pyrrolopyridineamino derivatives
NZ605432A (en) 2-(arylamino)-3h-imidazo[4,5-b]pyridine-6-carboxamide derivatives and their use as mpges-1 inhibitors
BR112013011991A2 (pt) composto, composição farmacêutica, uso de um composto, método de tratamento, produto, e kit.
TN2018000078A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
MX2010008418A (es) Derivados de pirido-[4,3-d]-pirimidinona como inhibidores de cinasa.
PE20130376A1 (es) [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer
SI2041133T1 (sl) Imidazo (1,2,a)piridin-2-karboksamidni derivati, njihova priprava in njihova uporaba v terapevtiki
SG10201806565SA (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
MX2013011854A (es) Compuestos de pirazol[3,4-b]piridina tri- y tetraciclica como agentes antineoplasicos.
MX2016015762A (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaspiro undecano que tienen actividad multimodal contra el dolor.
WO2009021965A3 (en) Substituted quinoline derivatives as h1 receptor antagonists
MX2022014168A (es) Sal y formas de cristal de 4-amino-5-(6-(4-metilpiperazin-1-il)-ih benzo[d]imidazol-2-il)tieno[2,3-b]piridin-6(7h)-ona.
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
WO2021009676A8 (en) Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonists
MA39715A (fr) Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation
MX367772B (es) Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk.
UY31588A1 (es) Derivados de imidazo[1,2-a]piridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
MX2019010756A (es) Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).